At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 35 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration or Macular Edema Secondary to Retinal Vein Occlusion to Evaluate the Usability of Lucentis® 0.5 mg Prefilled Syringe
In Brief
A Phase 3 clinical trial evaluating Ranibizumab for Macular Edema. Completed, enrolled 35 participants across 4 sites.
Detailed Summary
This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMar 2016
Primary CompletionApr 2016
TodayJul 2026
First PostedMar 3, 2016
Enrollment StartMar 21, 2016
Primary CompletionApr 5, 2016
TodayJul 2, 2026
Enrollment to primary: 14 daysPosted 10.3 years ago
Interventions
Ranibizumabdrug
Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.